Repros Therapeutics Inc. Reports Interim Safety Results From Ongoing One-Year Open Label Study of Proellex(R) in the Treatment of Uterine Fibroids

March 31, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX - News) announced today that the safety of Repros’ drug Proellex® appears to be enhanced with repeated cycles of treatment followed by off drug intervals.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase II